Antigen-specific T cell therapies for cancer

Human Molecular Genetics

Volumn 24, Issue R1, 2015, Pages R67-R73

  Manzo, Teresa ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CANCER; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TARGET CELL; TUMOR MICROENVIRONMENT; WART VIRUS; BIOLOGICAL THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84943741883     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv270     Document Type: Review

References (52)

1. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M. et al. (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 224ra25.
2. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F. et al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 371, 1507-1517.
3. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N. et al. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 385, 517-528.
4. Bollard, C.M., Rooney, C.M. and Heslop, H.E. (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat. Rev. Clin. Oncol., 9, 510-519.
5. Doubrovina, E., Oflaz-Sozmen, B., Prockop, S.E., Kernan, N.A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J.F., Heller, G., Barker, J.N. et al. (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood, 119, 2644-2656.
6. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, C.M., Liu, H., Wu, M.F., Rochester, R.J. et al. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925-935.
7. Bollard, C.M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E.J. et al. (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol., 32, 798-808.
8. Comoli, P., Pedrazzoli, P., Maccario, R., Basso, S., Carminati, O., Labirio, M., Schiavo, R., Secondino, S., Frasson, C., Perotti, C. et al. (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol., 23, 8942-8949.
9. Chia, W.K., Teo, M., Wang, W.W., Lee, B., Ang, S.F., Tai, W.M., Chee, C.L., Ng, J., Kan, R., Lim, W.T. et al. (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol. Ther., 22, 132-139.
10. Louis, C.U., Straathof, K., Bollard, C.M., Ennamuri, S., Gerken, C., Lopez, T.T., Huls, M.H., Sheehan, A., Wu, M.F., Liu, H. et al. (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J. Immunother., 33, 983-990.
11. Stevanovic-, S., Draper, L.M., Langhan, M.M., Campbell, T.E., Kwong, M.L., Wunderlich, J.R., Dudley, M.E., Yang, J.C., Sherry, R.M., Kammula, U.S. et al. (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol., 33, 1543-1550.
12. Pardoll, D.M. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 12, 252-264.
13. Vanneman, M. and Dranoff, G. (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer, 12, 237-251.
14. Cen, H., Williams, P.A., McWilliams, H.P., Breining, M.C., Ho, M. and McKnight, J.L. (1993) Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood, 81, 1393-1403.
15. Kelly, G.L., Stylianou, J., Rasaiyaah, J., Wei, W., Thomas, W., Croom-Carter, D., Kohler, C., Spang, R., Woodman, C., Kellam, P. et al. (2013) Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. J. Virol., 87, 2882-2894.
16. Schmitt, A., Tonn, T., Busch, D.H., Grigoleit, G.U., Einsele, H., Odendahl, M., Germeroth, L., Ringhoffer, M., Ringhoffer, S., Wiesneth, M. et al. (2011) Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion, 51, 591-599.
17. Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., Prevalsek, D., Jaeger, G., Ledderose, G. et al. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood, 115, 2960-2970.
18. Gerdemann, U., Keirnan, J.M., Katari, U.L., Yanagisawa, R., Christin, A.S., Huye, L.E., Perna, S.K., Ennamuri, S., Gottschalk, S., Brenner, M.K. et al. (2012) Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol. Ther., 20, 1622-1632.
19. Cobbold, M., Khan, N., Pourgheysari, B., Tauro, S., McDonald, D., Osman, H., Assenmacher, M., Billingham, L., Steward, C., Crawley, C. et al. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med., 202, 379-386.
20. Icheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, M.H., Schwinger, W., Nathrath, M. et al. (2013) Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol., 31, 39-48.
21. Uhlin, M., Okas, M., Gertow, J., Uzunel, M., Brismar, T.B. and Mattsson, J. (2010) A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol. Immunother., 59, 473-477.
22. Papadopoulou, A., Gerdemann, U., Katari, U.L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A.P., Vera, J. F. et al. (2014) Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci. Transl. Med., 6, 242ra83.
23. Kuppers, R., Engert, A. and Hansmann, M.L. (2012) Hodgkin lymphoma. J. Clin. Invest., 122, 3439-3447.
24. Bollard, C.M., Gottschalk, S., Leen, A.M., Weiss, H., Straathof, K.C., Carrum, G., Khalil, M., Wu, M.F., Huls, M.H., Chang, C.C. et al. (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 110, 2838-2845.
25. Cho, S.-G., Kim, N., Sohn, H.-J., Lee, S.K., Oh, S.T., Lee, H.-J., Cho, H.-I., Yim, H.W., Jung, S.E., Park, G. et al. (2015) Longterm outcome of extranodal NK/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs. Mol. Ther. doi: 10.1038/mt.2015.91.
26. Straathof, K.C., Bollard, C.M., Popat, U., Huls, M.H., Lopez, T., Morriss, M.C., Gresik, M.V., Gee, A.P., Russell, H.V., Brenner, M.K. et al. (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood, 105, 1898-1904.
27. Ramos, C.A., Narala, N., Vyas, G.M., Leen, A.M., Gerdemann, U., Sturgis, E.M., Anderson, M.L., Savoldo, B., Heslop, H.E., Brenner, M.K. and Rooney, C.M. (2013) Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J. Immunother., 36, 66-76.
28. Hanley, P.J., Melenhorst, J.J., Nikiforow, S., Scheinberg, P., Blaney, J.W., Demmler-Harrison, G., Cruz, C.R., Lam, S., Krance, R.A., Leung, K.S. et al. (2015) CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo. Sci. Transl. Med., 7, 285ra63.
29. Prockop, S.E., Doubrovina, E., Baroudy, K., Boulad, F., Khalaf, R., Papadopoulos, E., Sauter, C.S., Szenes, V., Suser, S., Wasilewski, G. et al. (2015) Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts. J. Clin. Oncol., 33 (suppl.), Abstract 10016.
30. Leen, A.M., Bollard, C.M., Mendizabal, A.M., Shpall, E.J., Szabolcs, P., Antin, J.H., Kapoor, N., Pai, S.Y., Rowley, S.D., Kebriaei, P. et al. (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 121, 5113-5123.
31. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C. et al. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123-1131.
32. Vickers, M.A., Wilkie, G.M., Robinson, N., Rivera, N., Haque, T., Crawford, D.H., Barry, J., Fraser, N., Turner, D.M., Robertson, V. et al. (2014) Establishment and operation of a goodmanufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br. J. Haematol., 167, 402-410.
33. Rosenberg, S.A. and Restifo, N.P. (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348, 62-68.
34. Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S. et al. (2014) Cancer immunotherapy based on mutationspecific CD4+ T cells in a patient with epithelial cancer. Science, 344, 641-645.
35. Vonderheide, R.H. (2002) Telomerase as a universal tumorassociated antigen for cancer immunotherapy. Oncogene, 21, 674-679.
36. Andersen, M.H., Pedersen, L.O., Capeller, B., Brocker, E.B., Becker, J.C. and thor Straten, P. (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res., 61, 5964-5968.
37. Rapoport, A.P., Aqui, N.A., Stadtmauer, E.A., Vogl, D.T., Fang, H.B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G. et al. (2011) Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood, 117, 788-797.
38. Gerdemann, U., Katari, U., Christin, A.S., Cruz, C.R., Tripic, T., Rousseau, A., Gottschalk, S.M., Savoldo, B., Vera, J.F., Heslop, H.E. et al. (2011) Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol. Ther., 19, 2258-2268.
39. Chapuis, A.G., Thompson, J.A., Margolin, K.A., Rodmyre, R., Lai, I.P., Dowdy, K., Farrar, E.A., Bhatia, S., Sabath, D.E., Cao, J. et al. (2012) Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc. Natl Acad. Sci. USA, 109, 4592-4597.
40. Chapuis, A.G., Ragnarsson, G.B., Nguyen, H.N., Chaney, C.N., Pufnock, J.S., Schmitt, T.M., Duerkopp, N., Roberts, I.M., Pogosov, G.L., Ho, W.Y. et al. (2013) Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in posttransplant patients. Sci. Transl. Med., 5, 174ra27.
41. Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A. and Yee, C. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med., 358, 2698-2703.
42. Robbins, P.F., Kassim, S.H., Tran, T.L., Crystal, J.S., Morgan, R. A., Feldman, S.A., Yang, J.C., Dudley, M.E., Wunderlich, J.R., Sherry, R.M. et al. (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res., 21, 1019-1027.
43. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M. et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother., 36, 133-151.
44. Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., Litzky, L., Bagg, A., Carreno, B.M., Cimino, P.J. et al. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122, 863-871.
45. Cole, D.K., Miles, K.M., Madura, F., Holland, C.J., Schauenburg, A.J., Godkin, A.J., Bulek, A.M., Fuller, A., Akpovwa, H.J., Pymm, P.G. et al. (2014) T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J. Biol. Chem., 289, 628-638.
46. Bollard, C.M., Rossig, C., Calonge, M.J., Huls, M.H., Wagner, H. J., Massague, J., Brenner, M.K., Heslop, H.E. and Rooney, C.M. (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99, 3179-3187.
47. Leen, A.M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H.E., Rooney, C.M. et al. (2014) Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther., 22, 1211-1220.
48. Armand, P. (2015) Immune checkpoint blockade in hematologic malignancies. Blood, 125, 3393-3400.
49. Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., Powderly, J.D., Heist, R.S., Carvajal, R.D., Jackman, D.M. et al. (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol., 33, 2004-2012.
50. Weber, J.S., D-Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H. Jr, Lao, C.D. et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, openlabel, phase 3 trial. Lancet Oncol., 16, 375-384.
51. Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B. and Dotti, G. (2014) Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res., 74, 5195-5205.
52. Dickinson, M., Johnstone, R.W. and Prince, H.M. (2010) Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest. New Drugs, 28 (Suppl. 1), S3-S20.